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Background: Ocular gene transfer clinical trials are raising hopes for blindness treatments and attracting media
attention. News media provide an accessible health information source for patients and the public, but are often
criticized for overemphasizing benefits and underplaying risks of novel biomedical interventions. Overly optimistic
portrayals of unproven interventions may influence public and patient expectations; the latter may cause patients
to downplay risks and over-emphasize benefits, with implications for informed consent for clinical trials. We analyze
the news media communications landscape about ocular gene transfer and make recommendations for improving
communications between clinicians and potential trial participants in light of media coverage.
Methods: We analyzed leading newspaper articles about ocular gene transfer (1990-2012) from United States (n = 55),
Canada (n = 26), and United Kingdom (n = 77) from Factiva and Canadian Newsstand databases using pre-defined coding
categories. We evaluated the content of newspaper articles about ocular gene transfer for hereditary retinopathies,
exploring representations of framing techniques, research design, risks/benefits, and translational timelines.
Results: The dominant frame in 61% of stories was a celebration of progress, followed by human-interest in 30% of
stories. Missing from the positive frames were explanations of research design; articles conflated clinical research with
treatment. Conflicts-of-interest and funding sources were similarly omitted. Attention was directed to the benefits of
gene transfer, while risks were only reported in 43% of articles. A range of visual outcomes was described from slowing
vision loss to cure, but the latter was the most frequently represented even though it is clinically infeasible. Despite the
prominence of visual benefit portrayals, 87% of the articles failed to provide timelines for the commencement of clinical
trials or for clinical implementation.
Conclusions: Our analysis confirms that despite many initiatives to improve media communications about experimental
biotechnologies, media coverage remains overly optimistic and omits important information. In light of these findings,
our recommendations focus on the need for clinicians account for media coverage in their communications with
patients, especially in the context of clinical trial enrolment. The development of evidence-based communication
strategies will facilitate informed consent and promote the ethical translation of this biotechnology.
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Informed consentBackground
The field of gene transfer, colloquially known as ‘gene
therapy’, has followed a trajectory of high hopes and
high profile failures. Historical abuses, including non-
disclosure of serious adverse events and highly publicized
conflicts-of-interest, have damaged its reputation [1-3],* Correspondence: tbubela@ualberta.ca
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distribution, and reproduction in any mediumeroded public trust, and presented significant setbacks
for its clinical development [4,5].
Ocular applications may yet rescue the reputation of
gene transfer with successful clinical trials beginning in
2007. Phase I clinical trials for Leber congenital amaurosis
(LCA), a rare, blinding retinopathy, established both
indexes of safety and improved visual function, despite
the small size and safety focus of first-in-human phase I
clinical trials [6-8]. Phase I trials are followed by larger
phase II trials that continue to test safety and establishd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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commonly randomized, controlled trials, are then statisti-
cally powered to test efficacy for primary (e.g., visual
acuity) and secondary (e.g., retinal imaging) outcome
measures. Sustained safety results for LCA [9] have led to
a phase III clinical trial at the University of Pennsylvania,
which is currently recruiting children (clinicaltrials.gov:
NCT00999609). Developments in LCA trials have served
as an impetus for further clinical trials for related ocular
diseases [10], including Stargardt disease (clinicaltrials.
gov: NCT01367444), retinitis pigmentosa (clinicaltrials.
gov: NCT01482195), Usher syndrome (clinicaltrials.gov:
NCT01505062), and choroideremia (clinicaltrials.gov:
NCT01461213).
These recent advances in ocular gene transfer have
triggered media attention [11], raising patient hopes
[12] for the mediation of previously untreatable genetic
diseases. News media are the most accessible source of
information on biomedical research for the public and
patients [13]. Media coverage, therefore, if exaggerated or
misrepresentative of gene transfer, may influence societal
and patient expectations.
News media are often blamed for distorting the impact
of biotechnology research through overly aversive or
favorable communications [13,14]. Media use frames
(simplified, interpretive representations of an issue) to
highlight the importance of an issue and how it should
be addressed [15]. Frames often bias contentious scientific
issues by placing greater emphasis on certain consider-
ations while omitting others [16]. For example human
embryonic stem cell research may be framed as ethically
unjustifiable for its destruction of embryos or as an ethical
imperative to provide cures for otherwise incurable
diseases [17,18]. Biomedical reporting is often criticized
for its framing that uncritically celebrates progress in
research [19]. Such framing emphasizes benefits over
risks [20], and omits crucial information such as funding
sources and potential conflicts-of-interest [21,22]. The
coverage often presents pre-clinical research (i.e., in-vitro
or animal studies) as an imminent therapy or cure [20].
From a clinical perspective, the uncritical progress
frame may lead clinicians, patients, and their families to
form high expectations, only to be disappointed when
reality falls short of hope, causing disillusionment among
clinicians and despair among patient communities [23].
In the context of clinical trials, overly positive media
coverage about research in progress may present challenges
to enrolment and informed consent in ongoing or subse-
quent clinical trials by heightening patient expectations
for therapeutic benefits [24]. In particular, potential partic-
ipants may misunderstand the safety focus of early-phase
trials and expect therapeutic outcomes [25].
As ocular gene transfer clinical trials for hereditary
retinopathies increase in number and reach phase III,attention must be directed at facilitating ethical communi-
cations of risks and potential benefits for recruitment of
clinical trial participants. Such communications will occur
in an environment of heightened media coverage, with
media influencing patient and public perspectives about
pre-clinical and clinical gene transfer research. Here, we
ask how newspaper articles report on ocular gene transfer
for hereditary retinopathies, exploring errors of omission
and biases in representations of framing, risks and bene-
fits, as well as therapeutic potential. Our analysis suggests
the need for clinicians to account for media coverage in
their communications with patients, especially in the
context of clinical trial enrolment. Evidence-informed
communication strategies set against the media landscape
will ensure the ethical translation of this biotechnology as
it moves forward to clinical application.
Methods
We examined newspaper communication about ocular
gene transfer between January 1, 1990 and June 30, 2012
in the top 50 United States (US), Canadian, and United
Kingdom (UK) newspapers by circulation [26]. We selected
1990 as our start year because it corresponds to the first
approved gene transfer clinical trial. These countries ranked
within the top ten for production of gene transfer trials
[27]; ocular gene transfer trials have commenced in the
US and UK and will shortly commence in Canada. We
used search algorithms for ‘ocular gene transfer’ in
media databases Factiva and Canadian Newsstand. The
initial search produced 2070 articles (84 Canadian, 647
UK, and 1339 US). After reading each article, we excluded
all but original articles about gene transfer targeting
retinopathies, resulting in 158 articles (26 Canadian, 55
US, and 77 UK) for analysis (Table 1).
We used pre-determined coding categories for our con-
tent analysis. The coding categories were modified from
pre-existing studies about media coverage of health re-
search and biotechnologies [28,29] and adapted to include
issues raised in similar studies [30-32]. Furthermore, the
coding categories were developed in response to issues
raised by forty-one semi-structured interviews with stake-
holders of a phase I ocular gene transfer clinical trial
(choroideremia patients, clinicians, and patient advocates).
A thematic analysis of these interviews revealed high
therapeutic hopes, limited attention to risks, and confu-
sion about the timelines for the clinical application of gene
transfer among patients [33]. The final coding categories
investigated the attention structure of newspaper articles
(word count, page number, news format), disease repre-
sentations, key categories of spokespeople, one dominant
frame for each article, use of human-interest stories, tone
of coverage, description of methods, representations of
timelines for translational research and clinical imple-
mentation, and representations of risks/benefits. Tone
Table 1 Search algorithms for ocular gene transfer newspaper articles in Factiva and Canadian Newsstand
Country Search strategya Number of articles Number of articles on
retinopathies for analysis
United States At least one of these words: blind* ocular ophtha* vision sight retin* eye 1339 55
This exact phrase: gene therapy
Canada TITLE (blind* OR ocular OR ophtha* OR vision OR sight OR retin* OR eye)
AND (gene therap*)
647 26
United Kingdom At least one of these words: blind* ocular ophtha* vision sight retin* eye 84 77
This exact phrase: gene therapy
aA truncation symbol (*) was used to capture alternative word endings of search terms (e.g. retin* captures retina, retinas, retinopathy, retinopathies, etc.).
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titative (number of benefits stated versus number of risks)
and qualitative (prominence and stated magnitude of ben-
efits versus risks) assessments. If the article stated more
benefits than risks, its tone was positive. However, where
benefits and risks were equal in number, we considered
their respective magnitude. For example, a benefit of “cure
for blindness” versus the economic risk of “expense of the
clinical trial” also indicated a positive tone.
A research assistant coded all articles, and one of the
authors [SB] independently coded 19% to verify that a
second coder would arrive at the same conclusion as the
main coder. We calculated Cohen’s Kappa for inter-coder
reliability (SPSS 18: IBM). Kappa scores ranged between
0.71-1.0, displaying acceptable inter-coder agreement
[34]. To accommodate the small sample size of Canadian
newspaper articles, we used Fischer’s chi squared tests
(STATA 11: StataCorp 2009) to assess differences in
coverage between countries. We used a Kruskal-Wallis
Analysis of Variance (STATA 11: StataCorp 2009)—a
non-parametric alternative to a one-way analysis of
variance—to assess differences in the median number
of benefit and risk representations between countries.
We combined articles from the three countries when
there was no significant difference in coverage (α = 0.05).
Results
Most articles were published in the main news section
with only 1% of articles appearing as front-page news.
The average article word length was 615 words. Ninety
two percent of articles were formatted as “latest news”,
and a minority was formatted as interviews (3%), com-
mentaries (3%), and editorials (2%). The articles covered a
variety of retinopathies; some currently under the investi-
gation of clinical trials and some that have not advanced
beyond pre-clinical studies (Table 2). The distribution of
newspaper articles over time is displayed in Figure 1.
Dominant spokespeople and frames
The most frequently quoted spokespeople were researchers
from universities, research institutes or government; fol-
lowed by patient advocacy organization representatives
and affected individuals and their families (Table 3). Themajority of Canadian and UK articles quoted a researcher
compared to 38% of US articles (Table 3). Industry quotes
were scarce in all countries with only a single article inter-
viewing a private sector scientist and a second represent-
ing the views of a biotechnology company spokesperson.
Largely missing were experts on legal or ethical issues.
The dominant frame in 61% of all stories was a celebra-
tion of progress in research with no significant difference
in framing across countries. For example, a patient advo-
cate was quoted as saying: “It’s really nothing short of
miraculous, .... You’re talking about being able to restore
vision in animals that are, essentially, totally blind. This
is kind of the first fruit of the revolution in genetic
medicine.” [35]. Forty-seven of total articles (30%) were
dominantly framed as human-interest stories, and 68%
of these depicted the challenges of affected individuals
living with genetic retinopathies. Forty percent of human-
interest stories portrayed affected patients as heroic or
hopeful, while only one article conveyed the challenges of
affected individuals through a lens of fatalism, depicting
sorrow and hopelessness. The challenges of family mem-
bers of affected individuals were described in 17% of
the human-interest stories, and narratives of heroism
and hope were present in 19%. While researchers were
frequently quoted in articles, only 4% presented human-
interest stories on gene transfer researchers, portraying
them as heroes. The remainder of the articles (8%) was
presented using a descriptive frame, and displayed a neu-
tral account of the science [16]. Other common frames in
science journalism—such as conflict (the dominant frame
in coverage of politically charged science topics such as
climate change and evolution), economic development,
morality, scientific uncertainty, risk, and public account-
ability [32]—were absent.
Research design explanations
Explanations of research design lacked detail and context
in all countries (Table 4). Most striking was the subtle
conflation of research and treatment, for example, “[t]o
hear such quick progress in a gene therapy treatment is
fantastic. We hope this success will lead to more funding
of gene therapy research into conditions that currently
have no cure or treatment” [emphasis added] [36].
Table 2 Retinopathies represented in newspaper articles compared to phase of clinical trials registered in clinicaltrials.gov
Diseaseb
(number of articlesa)








Progressive retinopathy with severe
visual problems beginning in infancy.
NCT00999609 III RPE65 Adeno-associated viral vector;
AAV2-hRPE65v2
n = 24; 3 years and older
NCT00749957 I/II RPE65 Recombinant adeno-associated
viral vector; rAAV2-CB-hRPE65
n = 12; 6 years and older
NCT01208389 I/II RPE65 Adeno-associated viral vector;
AAV2-hRPE65v2
n = 12; 8 years and older
NCT00643747 I/II RPE65 Recombinant adeno-associated viral
vector; rAAV 2/2.hRPE65p.hRPE65
n = 12; 5-30 years old
NCT01496040 I/II RPE65 Recombinant adeno-associated
viral vector; rAAV-2/4.hRPE65
n = 9; 6-50 years old
NCT00481546 I RPE65 Recombinant adeno-associated
viral vector; rAAV2-CBSB-hRPE65
n = 15; 8 years and older
NCT00821340 I RPE65 Recombinant adeno-associated
viral vector; rAAV2-hRPE65
n = 10; 8 years and older
NCT00516477 I RPE65 Adeno-associated viral vector;
AAV2-hRPE65v2
n = 12; 8 years and older
Retinitis pigmentosa (37) Progressive retinopathy characterized
by gradual peripheral vision loss
NCT01482195 I MERTK Recombinant adeno-associated viral
vector; rAAV2-VMD2-hMERTK
n = 6; 14-70 years old
Age-related macular
degeneration (24)
Progressive central vision loss usually
occurring in older adults
NCT01301443 I Genes that encode
endostatin and angiostatin
Lentiviral vector; RetinoStat n = 18; 50 years and older
NCT01678872 I Genes that encode
endostatin and angiostatin
Lentiviral vector; RetinoStat n = 18; 50 years and older
Choroideremia (7) Progressive retinopathy characterized
by gradual peripheral vision loss
NCT01461213 I/II REP1 Adeno-associated viral vector;
AAV.REP1
n = 12; 18 years and older
Stargardt macular
degeneration (7)
Progressive degeneration of the
macula causing central vision
loss beginning in childhood
NCT01367444 I/IIa ABCA4 Lentiviral vector; StarGen n = 28; 18 years and older
Usher syndrome (7) Progressive retinopathy (retinitis
pigmentosa) combined with hearing loss
NCT01505062 I/IIa MYO7A Lentiviral vector; UshStat n = 18; 18 years and older
aSome articles targeted more than a single retinopathy.



















































Figure 1 Distribution of newspaper articles about ocular gene transfer over time.
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sizes in research, and 87% of articles failed to indicate
the phases of clinical trials. Canadian articles were more
likely to discuss pre-clinical studies (i.e., in vitro or animal
studies), while a greater proportion of UK and US articles
discussed clinical trials (Table 4). UK articles were half
as likely (48%) to state that a gene mutation caused the
genetic retinopathy under investigation, compared to
Canadian (77%) and US (71%) articles. However, US
articles were least accurate in their reporting of the
function of gene transfer and the mechanics of its delivery
(Table 4). Funding sources were mentioned in only 39%
of all articles. Only 3% of articles described controversies
and conflicts-of-interest. For example, controversy over
the benefits of gene transfer for patients, who had adjusted
to their visual impairment was described: “[w]hile the
prospect of a cure is exciting, it can also be scary for
people living with limited or no sight …. If they said,
‘there’s a cure and you’re going to be able to see’, they
wouldn’t just jump and say, ‘Yes!’ Because the wholeTable 3 Categories of spokespeople quoted in Canadian, Unit
Spokespersona Percent (%) of articles




Patient advocacy organizations 27 10
Affected individuals 19 27
Family of affected individuals 19 11
Friends of affected individuals 4 4
Ethics committees 4 1
Parliament/Congress 4 5
Media/Columnist opinion 8 16
aCategories are not mutually exclusive, therefore add to >100%.
bStatistically significant differences (p<0.05) are indicated by *.world would change on them, … They’ve both been
able to carry on with their lives without sight. Then all
of a sudden if you could see it wouldn’t make sense …
They wouldn’t be able to read” [37].
Representations of risks, benefits, and timelines
The tone of newspaper coverage was overwhelmingly
positive in all countries (Figure 2). Benefits were dispro-
portionately represented with a median of three benefits
compared to a median of 0 risks (only 43% of articles
described any risk) (Table 5). While some statistical dif-
ferences existed among countries in reporting of risks,
these are due to the very low percentages of articles
that discussed specific risks (Table 5). The commonality
among countries was the lack of reporting of risks. In
general, no risks were mentioned in 35% of Canadian,
69% of UK, and 53% of US articles. In contrast, all articles
discussed benefits; visual improvement was prominently
represented in Canadian (100%), UK (91%), and US (87%)
articles. Representations of visual benefit ranged along aed Kingdom, and United States newspapers
P-valueb









Table 4 Research design explanations in Canadian, United Kingdom, and United States newspapers







Gene transfer is research 0.069
Clearly mentioned 23 39 47
Mentioned, but research/treatment conflation 77 51 45
Sample sizes stated 42 29 40 0.274
Phase of clinical trial 0.000*
Mentioned 4 3 5
Not applicable 27 0 0
Gene mutation causes genetic retinopathies 77 48 71 0.006*
Working copy of mutated gene is transferred to ameliorate disease phenotype 0.000*
Mentioned with accuracy 58 53 21
Mentioned, but incorrect/misleading terminology (e.g. Gene replacement) 15 3 18
Viral vector transports the gene of interest 0.078
Explained accurately 35 23 18
Explained, but viral modification not mentioned 23 8 13
Working gene is transferred to the back of the eye 65 61 38 0.015*
Gene transfer involves eye surgery 62 56 38 0.063
aStatistically significant differences (p<0.05) are indicated by *.
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loss to a cure. For example, one article claimed, “REVO-
LUTIONARY gene therapy can cure a severe form of
inherited blindness in days, groundbreaking trials show”
[38]. Indeed, the more therapeutic the outcome along the
continuum, the more frequently it was represented in
newspaper articles (Figure 3); slowing down vision loss
was rarely discussed compared to complete cure. No art-
icle indicated that deriving visual benefit from ocular gene
transfer might be unlikely.
While the majority of articles predicted visual benefit
as an outcome of ocular gene transfer, 87% of all articles
did not provide estimates of timelines for the com-



























Figure 2 Tone of ocular gene transfer in newspaper articles
from Canada, United Kingdom and United States.the regulatory process, or the clinical implementation
of this biotechnology. Table 6 provides examples of
statements that predict timelines for the translation of
gene transfer research.Discussion
Our analysis of newspaper coverage of ocular gene transfer
identifies persistent challenges posed by overly positive
representations of experimental biotechnologies in all three
countries analysed. Sensationalism in the news media is
seldom present as blatantly inaccurate reporting [20,28,31].
Instead, as for ocular gene transfer, overly enthusiastic or
exaggerated claims are evident through biased framing,
errors of omission, and an emphasis on benefits over risks.
Such overly optimistic reporting serves to discredit media
claims [39] and build heightened social expectations about
the promise of emerging biotechnologies [40]. As such,
the research community, policy makers, and ethicists
view a lack of balance in media reporting as a major
shortcoming [20].
Our analysis of newspaper coverage of ocular gene trans-
fer identified minor differences in coverage in Canadian,
UK and US print media, but the same essential concerns
persisted. Coverage in all three countries focused on
human-interest stories, dominant framing as a “celebration
of progress”, and had limited discussion of risks, research
design, conflicts-of-interest, funding sources, and research
timelines. US news articles were least likely to discuss the
Table 5 Ocular gene transfer risks and challenges in Canadian, United Kingdom, and United States newspapers
Gene transfer risks, challenges, or caveats Percent (%) of articles P-valuea
Canada (n = 26) United Kingdom (n = 77) United States (n = 55)
Not mentioned 35 69 53 0.006*
General health risk 19 17 33 0.098
Efficacy concerns 35 9 18 0.003*
New research or first-in-human experimentation 12 8 5 0.607
Long timeline to clinical implementation 15 5 4 0.002*
Historical adverse events in gene transfer clinical trials 8 0 11 0.006*
Eye health risk 8 3 7 0.299
Unknown risk/Uncertain risk 15 0 5 0.003*
Complexity of gene transfer 4 6 0 0.143
Economic risk 11 0 0 0.004*
Ethical challenges 4 0 0 0.075
Social challenges 0 1 0 1.000
Quality of life concerns arising from clinical trial participation 4 0 0 0.165
Legal risk 0 0 0 1.000
aStatistically significant differences (p<0.05) are indicated by *.
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in their depiction of the purpose and methodology of
gene transfer. Differences in coverage patterns were
likely due to the number of articles in newspapers of
varying quality per country (e.g., national versus local
and broadsheet versus tabloid) and attention to local
research. For example, Canadian articles reported more
pre-clinical research, reflecting the state of gene transfer
in Canada.
Recommendations to address these media challenges
are many and include describing scientific roadblocks
and the possibility of findings being invalidated by
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Figure 3 Representations of ocular gene transfer visual outcomes
in newspaper articles from Canada, United Kingdom, and
United States.independent sources of information about the implica-
tions of scientific advances [41]; and encouraging re-
searchers to disclose conflicts-of-interest to reporters
[21,22]. Proposed educational strategies to promote bal-
anced reporting include training researchers to “stick to
the facts” when communicating with reporters; training
graduate students—as future spokespeople—in effective
science communication strategies [20]; inviting reporters
to scientific conferences; and creating accessible materials
to educate the news media about scientific advances [42].
Unfortunately, these recommendations do not adequately
account for the nature of news media, which, as businesses,
face their own pressures. Journalists produce copy within
limited deadlines and compete fiercely for editorial and
public attention. While increasing web content expands
potential to provide further background material, print and
television media still face space or time constraints. Our
findings on frames and emphasis of benefits over risks
highlight that ocular gene transfer is seen as a “good news”
story for the visually impaired and their families. Our
analysis confirms that decades of recommendations and
initiatives to improve the tenor and content of science
journalism have resulted in limited discernible improve-
ment, at least, in the context of ocular gene transfer. As a
result, recommendations may be more tractable at the
level of clinical communications between clinicians and
patient communities. Here, we first place our results in
the context of other studies and then recommend the
development of communication strategies between clini-
cians and their patients, especially potential clinical trial
participants, that operate within the landscape of overly
optimistic media coverage.
Table 6 Illustrative timeline estimates for ocular gene transfer clinical trials or clinical application
Timeline estimate Predicted year
for outcome
Outcome Source
“Bennett, an associate professor of ophthalmology
at the University of Pennsylvania…said she hopes
initial experiments in people can begin within
about two years.”
2003 Leber congenital amaurosis clinical trials
began in 2007, with phase-I results published
in 2008 (Bainbridge et al., [6]; Hauswirth
et al., [7]; Maguire et al., [8]).
Anonymous: Gene therapy restores
dogs’ eyesight, may treat blind.
Houston Chronicle; 2001, April 28.
“Within five years [gene transfer] could be ready
for testing on people who suffer age-related
macular degeneration.”
2013 Phase I clinical trials were initiated in
2010 (NCT01678872).
Highfield R: Hope of genetic cure
for failing eyesight.
The Daily Telegraph; 2008, April 28.
“This [phase-I gene transfer clinical trial for Leber
congenital amaurosis] really paves the way for
developing a treatment for people who have so
far had no prospect of a cure,” said Robin Ali, an
ophthalmologist at UCL… “Within two to three
years it might be approved for use in the clinic.”
2010-2011 Leber congenital amaurosis is currently
recruiting for a phase-III clinical trial
(NCT00999609).
Sample I: Maze walk marks ‘huge
advance’ in gene therapy for blindness.
The Guardian; 2008, April 28.
“[achromatopsia] treatment could be as little
as four or five years away.”
2016-2017 To be determined. Hilpen K: The boy who sees in
black and white. The Daily
Express; 2012, March 6.
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Researchers from universities and research institutes were
the dominant spokespeople, and clinical researchers, in
particular, were represented as heroes [43]. The public
places a high degree of trust in such researchers [44], and
their statements lend credibility to media reports. Ransoh-
off & Ransohoff characterize the relationship between
media and researchers as one of “complicit collaboration”
[39], both promoting promise as well as attracting funds
and public support [45]. Indeed, researchers who perceive
that media attention will promote their work are most
often represented in the news media [46]. As such, re-
searchers are compelled by careerist pressures and serve
as partisan stakeholders in media communications [13].
Human-interest stories focused on patients and families
[47,48], which presented the narrative of gene transfer
through a lens of hope, compassion, empowerment, and
heroism [49]. Such narratives are a “powerful way of both
universalizing and personalizing human experience” [50].
Emotive descriptions generate the most public conversation
and reflection [47]; capture the attention of policy makers;
and provide a platform for disease advocacy and funding
opportunities [48,51]. Nevertheless they may mask the
scientific information presented in media reports [47].
While newspaper articles, especially those with longer
format, may have more than one frame, in our dataset,
the dominant frame was a “celebration of progress”, which
was consistent with other novel medical biotechnologies
[19,32]. This frame generates the social expectations
necessary to sustain public support for gene transfer
[40], but detracts from risks and reinforces optimistic
messages of benefits [20]. Frames are most effective
when they resonate with audiences on a psychological
level [52]. As such, frames of progress may reinforce
the hopes of patients and their families.Often missing from the positive frames were explana-
tions of research design [53]—including sample size and
study phase—that conflated research with treatment.
Conflicts-of-interest or funding sources were similarly
omitted. Such omission diminishes transparency and the
ability of the public to critically evaluate the stakes of
interested and affected parties in the research effort
[28,31,53]. Funding or other conflicts-of-interest should
always be visible in media reports [21,22], especially in
consideration of the checkered history of gene transfer. An
early gene transfer trial for ornithine transcarbamylase defi-
ciency at the University of Pennsylvania, which resulted
in the death of a young participant, is regarded as “the
most famous conflict-of-interest case in medicine” [2].
It resulted in a loss of public trust [5], which is essential
for the sustainable translation of this biotechnology [54].
Supporting the positive framing was an overemphasis
on benefits at the expense of a discussion of risks
[28,31,53,55,56]. Risks are notoriously difficult to explain
to lay audiences, including journalists, because of in-
accessibility of probabilistic information [57]. Ethical and
social risks also go underreported [20,42,58], even though,
one study of social media indicated public concern about
these [59]. Most importantly, however, serious risks exist
for clinical research participants in ocular as well as other
gene transfer interventions. Oncogenic risks arise from
insertional mutagenesis and a severe immune response
to the viral vector has resulted in death [1]. Risks specific
to ocular gene transfer include surgical complications, loss
of an eye due to inflammation, loss of remaining vision,
as well as the very low risk of brain toxicity due to viral
vector integration into the optic nerve [6-8,33,60]. A
discussion of risks emphasizes the early-stage, experi-
mental nature of the technology, which has historically
been associated with risk and uncertainty.
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the focus of the articles [19,42,55,59]. Media emphasized
direct visual benefits, giving patients and families hope
for a similar outcome even though most reported studies
were pre-clinical or phase I trials, focused on safety not
efficacy. Additionally, media articles conflated goals of
research and of clinical care: a phenomenon that is termed
therapeutic misconception [61]. Therapeutic misonception
is ethically problematic because an understanding of
the goals of a clinical trial is necessary for autonomous
decision-making and informed consent for research
participants [62].
The extent to which media coverage contributes to
therapeutic misconception is not known. However, one
survey of prospective participants for a phase I oncology
clinical trial found that exposure to media reports did
not result in therapeutic misconception among patients
[63]: 47% of patients who first heard about the trial from
the news media correctly identified its purpose prior to
informed consent compared to only 15% of patients who
did not encounter media descriptions. Nevertheless,
therapeutic benefit was the most prominent motivator
for participation, meaning that therapeutic optimism can
coexist with a correct understanding of the purpose of a
phase I clinical trial [63].
More concerning is the news media focus on curative
discourse—a phenomenon common in media coverage
of prospective biotechnologies [49]. With respect to ocu-
lar gene transfer, however, the hope for a cure may be
misplaced. Jacobson et al. [64] demonstrated that while
vision loss can be halted and even improved by restoring
function of dormant but otherwise viable photoreceptors,
a cure is not theoretically afforded by gene transfer. This
is because gene transfer is non-regenerative, and therefore
cannot revive degenerated photoreceptors [64]. Recent
evidence also suggests that despite visual improvement,
retinal degeneration continues to progress in canine models
and humans after LCA gene transfer [65], meaning that
long-term efficacy may not be established through ocular
gene transfer alone.
Media representations of a cure, while catchy, are in-
accurate and misrepresent the theoretical promise of gene
transfer research. They leave potential clinical trial partici-
pants vulnerable to therapeutic misestimation, whereby
benefits are overestimated and risks underestimated
[62]. While therapeutic misestimation may sometimes
be ethically tolerable because an understanding of the
exact probability of benefit is not necessary to make an
autonomous decision about participation [62], curative
perspectives present a misestimation of the magnitude
of benefit rather than its probability. While it is impossible
to convey exact probabilities for benefits in novel clinical
trials, there is an ethical obligation to avoid raising patient
hopes for benefits known to be theoretically infeasible.Finally, the majority of articles failed to contextualize
timelines for clinical application of ocular gene transfer.
Media articles implied that therapeutic benefits were
imminent, despite their early stages of development.
Similarly, media portrayals of time estimates for gene
discoveries for psychiatric condition and the availability
of clinical services were largely unmet [58]. Such por-
trayals of present research outcomes may be ethically
problematic for patients, as they may inflate expectations
for a treatment in ongoing or future clinical trials and
set patients up for disappointment [23].
In summary, newspaper communications about ocular
gene transfer were replete with errors of omission and
employed optimistic frames commonly used to generate
social expectations about novel biotechnologies [40].
Benefits were over-represented and risks were often not
discussed. Moreover, the focus on curative language within
a therapeutic spectrum raises challenges for the ethical
communication about ocular gene transfer in the context
of recruiting clinical trials.Limitations
This study only examined newspaper coverage and not
Internet or television content, however, leading newspapers
have an agenda setting role, serving as a platform for other
media venues. With the exception of coding for curative
visual benefits, this study did not assess media bias through
“errors of commission” [20] as it did not compare the con-
tent of media coverage with that of scientific journal and
clinical publications. Despite this shortcoming, this study
explored the lack of balance in media reporting through
the more common forms of omission and framing biases
[28,31,32]. Finally, the study did not examine the impact of
media coverage directly on potential participants in recruit-
ing clinical trials and their families. While we interviewed
patients about the prospect of an ocular gene transfer
clinical trial for choroideremia and their responses
informed the coding frame, the proposed trial was not
yet recruiting participants.Conclusions
This study shows little improvement in science media
communication in the past decade, despite initiatives
to improve journalism on novel health technologies
[20,28,30,31,41,42,47]. Media reports continue to be
overly optimistic and framed as human-interest stories,
whether from the perspective of the heroic researcher
or hopeful patient. We therefore reiterate that clinicians
and researchers, in their encounters with the news
media, should be factual, balanced in addressing both
risks and benefits, disclose funding sources and conflicts-
of-interest, provide realistic timelines, and discourage
curative speculation when research is either in early
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further incentive for moderated media communications,
we support Kimmelman’s [66] recommendation that insti-
tutional review boards require investigators of clinical
trials to submit a portfolio of their press releases as a
component of ethics review [66].
At a more practical level, however, and one that is dir-
ectly in the control of researchers/clinicians, the onus
must be on these stakeholders to address the backdrop
of media coverage in the context of ongoing clinical care
and clinical trial enrolment. In particular, researchers and
clinicians must distinguish between the goals of research,
of the phases of clinical investigation, and treatment.
Additionally, clinical communicators must counter media
messaging, emphasizing to their patients that a cure will
not be afforded through gene transfer alone. Taking media
communications into account when discussing the poten-
tial of ocular gene transfer clinical trials will promote
‘informed hope’ among patients in the context of clinical
care [67], informed consent among research participants
in the context of recruiting trials, and facilitate the ethical
translation of this biotechnology as it moves towards
clinical application.
Abbreviation
LCA: Leber congenital amaurosis.
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